Michael Platt Backs UK Biotech Engitix in Strategic Investment

Hedge fund magnate Michael Platt has acquired a substantial stake in Engitix, a London-headquartered biopharmaceutical company focused on developing novel therapeutics for fibrotic diseases. The investment, confirmed through regulatory filings, represents a cornerstone commitment of £120 million ($153 million) into the company’s Series C financing round. This infusion of capital is expected to accelerate clinical development of Engitix’s lead candidate, ENG-701, a first-in-class inhibitor targeting TGF-β signaling pathways implicated in organ fibrosis. The funding will support Phase II trials across liver and lung fibrosis indications, with pivotal data anticipated by mid-2027. Engitix’s proprietary platform leverages precision molecular engineering to achieve targeted tissue delivery, reducing systemic exposure and improving safety profiles—an approach that has drawn interest from several institutional investors beyond Platt. Platt’s involvement underscores growing investor appetite for UK-based biotech innovation, particularly in niche therapeutic areas with high unmet medical need. His track record includes early-stage bets in companies like Sana Biotechnology and Moderna, where he achieved notable returns via strategic exits. Engitix’s market valuation has since risen to approximately £890 million post-investment, reflecting increased credibility among global healthcare investors. The investment also highlights a shift in capital allocation toward late-stage pre-commercial biotechs with defensible intellectual property. As clinical milestones approach, Engitix is poised to attract further institutional participation, potentially setting the stage for a future public offering or acquisition by a major pharmaceutical player.